Lung Cancer

Early Lung Cancer Trials

The American Cancer Society estimates that more than 170,000 Americans will be diagnosed with lung cancer in 1998. Lung cancer remains the leading cause of cancer death in the US among both men and women. More American will die of lung cancer than colon, breast, and prostate cancer combined. One of the major obstacles in treating lung cancer is its late presentation, when the options for treatment are primarily to relieve symptoms. When lung cancer is found early, however, majority of them can be cured by surgery. Recently, many advances have been made in diagnostic technology. These new diagnostic tools hold promise to the early detection of lung cancer.

As one of the leaders in the medical research community, UCLA is actively involved in several on going clinical trials designed to evaluate the effectiveness of various diagnostic tools for early lung cancer detection, including low dose CT scan, Fluorescence (LIFE) bronchoscopy, and specialized sputum analysis. The following is a synopsis of the various studies and clinical programs:

A Research Study for Early Detection and Prevention of Second Lung Cancer with Celebrex vs Placebo
LIFE (Fluorescence) Bronchoscopy Program

<< top